Skip to main content
Log in

Infliximab

A Review of its Use in the Management of Rheumatoid Arthritis

Drugs Aims and scope Submit manuscript

Summary

Abstract

Infliximab is a chimaeric monoclonal antibody to human tumour necrosis factor-α (TNFα). It binds to both soluble and transmembrane forms of TNFα at picomolar concentrations in vitro. Secondary to inhibition of TNFα, infliximab reduces serum levels of inflammatory mediators and vascular endothelial growth factor, decreases the expression of chemokines in the synovial tissue and reduces lymphocyte migration into the joints of patients with rheumatoid arthritis.

In 2 multicentre randomised double-blind trials conducted over 26 and 30 weeks, infliximab plus methotrexate was significantly more effective than placebo plus methotrexate according to American College of Rheumatology response criteria in patients with active rheumatoid arthritis. A substantial response to infliximab-containing regimens was evident within 2 weeks. Extension phases of these studies indicate sustained clinical efficacy for up to 54 weeks. Of considerable importance are preliminary 1-year radiographie findings that show zero median progression of joint damage in infliximab plus methotrexate recipients compared with a 7 to 8% deterioration in placebo plus methotrexate recipients.

Headache, nausea, upper respiratory tract infection and infusion-related reactions are the most commonly reported adverse events with infliximab. Serious events occurred in 4.4% of infliximab versus 1.8% of placebo recipients. In the largest clinical trial, 2 patients died from disseminated infection and 3 developed new or recurrent malignancies, although the exact relationship between infliximab and these events is unknown. To date, 2 patients with rheumatoid arthritis have developed drug-induced lupus. About 10% of patients may develop antibodies to infliximab, although the clinical significance of these is presently unknown.

Conclusion: Infliximab represents an important advance in the treatment of rheumatoid arthritis, with tolerability concerns raised by early studies having been eased somewhat by more recent data in larger patient numbers. If preliminary results indicating that infliximab is able to arrest joint destruction in patients with rheumatoid arthritis are corroborated, the drug will likely become an integral component of future management strategies for this difficult-to-treat condition.

Pharmacodynamic Properties

Infliximab is a chimaeric monoclonal antibody to human tumour necrosis factor-α (TNFα). It binds to both soluble and transmembrane forms of TNFα at picomolar concentrations in vitro but not to lymphotoxin (TNFβ).

Infliximab is thought to achieve clinical benefit in patients with rheumatoid arthritis by several mechanisms secondary to TNFα blockade. Firstly, infliximab reduces serum levels of inflammatory mediators [interleukin (IL)-1β and -6] and the expression of chemokines (IL-8 and monocyte chemoattractant protein-1) in the synovial tissue. Secondly, infliximab reduces lymphocyte migration as shown by decreased movement of radiolabelled granulocytes into the joints of patients with rheumatoid arthritis. This is accompanied by increases in peripheral lymphocyte counts. Thirdly, infliximab reduces serum levels of vascular endothelial growth factor in patients with rheumatoid arthritis which may in turn reduce angiogenesis in the joint. It also reduces serum levels of metalloproteinase-3 and nitric oxide synthase activity, changes which correlate with clinical benefit in patients with rheumatoid arthritis.

Infliximab is also associated with transient reductions in peripheral blood monocyte and neutrophil counts and increases in haemoglobin levels.

Pharmacokinetic Properties

Infliximab demonstrates dose-dependent pharmacokinetics over the dose range 1 to 20 mg/kg. No systemic accumulation of infliximab 3 or 10 mg/kg was observed when administered at 8-week intervals.

Serum concentrations of infliximab appear to be sustained for longer when the drug is administered in combination with methotrexate. Eight weeks after the last of 5 × 3 mg/kg doses, serum concentrations of infliximab were approximately 2 and <0.1 mg/L with and without concomitant methotrexate, respectively.

The volume of distribution (Vd) of infliximab at steady state is independent of dose, suggesting intravascular distribution. Median Vd ranges from 3 to 5L. The estimated elimination half-life of infliximab is 8 to 9.5 days.

Therapeutic Use

Monotherapy with infliximab, administered as a single 1 or 10 mg/kg dose, was associated with significant improvements in Paulus 20% response after 1 and 4 weeks in a randomised placebo-controlled double-blind trial in patients with active rheumatoid arthritis.

In patients receiving background methotrexate, 2 multicentre randomised double-blind trials have evaluated the effects of multiple doses of infliximab 1 to 10 mg/kg administered at 4- or 8-week intervals over 26 and 30 weeks. The more recent of these studies, the Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) study, is the most comprehensive analysis to date of the efficacy of infliximab in patients with refractory rheumatoid arthritis.

In each of these trials, infliximab plus methotrexate was significantly more effective than placebo plus methotrexate according to American College of Rheumatology (ACR) response criteria. A substantial response to infliximab-containing regimens was evident within 2 weeks in these studies. The duration of response improved as the dosage of infliximab increased.

Extension phases of these studies indicate sustained clinical response to continued infliximab therapy for up to 54 weeks. Of considerable importance are preliminary 1-year radiographic findings that show zero median progression of joint damage in infliximab recipients compared with a 7 to 8% deterioration in placebo plus methotrexate recipients.

Tolerability

In a pooled analysis, the overall incidence of adverse events was 76% in infliximab versus 57% placebo recipients. Headache, nausea, upper respiratory tract infection and infusion-related reactions occurred most frequently. Less frequently reported adverse events included abdominal pain, pharyngitis, fever, vomiting, coughing, rash, pain, rhinitis, sinusitis, urinary tract infection, fatigue and pruritus. Serious adverse events likely to be associated with treatment occurred in 4.4% of infliximab versus 1.8% of placebo recipients; these included pneumonia and fever, dyspnoea and rash.

Infection was reported in 26% of infliximab recipients versus 16% of placebo recipients after respective follow-up periods of 27 and 20 weeks. Two patients in the ATTRACT study died from infectious disease (disseminated tuberculosis and coccidomycosis) but the relationship between infliximab and these events is not known.

Seven malignancies occurred in patients treated with infliximab in clinical trials. It is not clear whether infliximab contributed to the development of these malignancies; however, rates are within expectations for the populations involved.

Antibodies to infliximab (ATI) can develop, although the clinical significance of these antibodies is unknown. ATI formation appears to be reduced by concomitant administration of methotrexate. In the ATTRACT trial, 3 of 27 patients who discontinued infliximab treatment were positive for the presence of ATI.

Antinuclear antibodies were detected in 23% of infliximab versus 6% of placebo recipients during the ATTRACT study, whereas antibodies to doublestranded DNA were detected in 16 versus 0% of patients. Two patients with rheumatoid arthritis have developed drug-induced lupus to date.

Dosage and Administration

The recommended dose of infliximab for the treatment of rheumatoid arthritis is 3 mg/kg given as an intravenous infusion. Additional doses should be administered 2 and 6 weeks after the initial dose, and every 8 weeks thereafter. The drug should be administered in combination with methotrexate.

Infliximab carries a warning regarding the risk of infections in patients treated with anti-TNF therapy. Caution is advised regarding the use of infliximab in patients with chronic infection or a history of recurrent infection and the drug is contraindicated in those with clinically important active infections. Infliximab should be discontinued in patients who develop serious infection, sepsis or symptoms suggestive of drug-induced lupus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Table II
Fig. 3
Fig. 4
Fig. 5
Table III

References

  1. Feldmann M, Elliott MJ, Woody JN, et al. Anti-tumor necrosis factor-a therapy of rheumatoid arthritis. Adv Immunol 1997; 64: 283–350

    Article  PubMed  CAS  Google Scholar 

  2. van der Heijde DMFM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995; 34 Suppl. 2: 74–8

    PubMed  Google Scholar 

  3. Maini RN. The role of cytokines in rheumatoid arthritis: the Croonian Lecture 1995. J R Coll Physicians Lond 1996 Jul–Aug; 30: 344–51

    PubMed  CAS  Google Scholar 

  4. Ohshima S, Saeki Y, Mima T, et al. Possible mechanism for the long-term efficacy of anti-TNF-α antibody therapy (cA2) in RA [abstract no. 1289]. Arthritis Rheum 1996 Sep; 39 Suppl.: S242

    Google Scholar 

  5. Furst DE, Breedveld FC, Kalden JR, et al. Building towards a consensus for the use of tumour necrosis factor blocking agents. Ann Rheum Dis 1999; 58(12): 725–6

    Article  PubMed  CAS  Google Scholar 

  6. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999 Jun; 57(6): 945–66

    Article  PubMed  CAS  Google Scholar 

  7. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30(16): 1443–53

    Article  PubMed  CAS  Google Scholar 

  8. Onrust SV, Lamb HM. Infliximab: a review of its use in Crohn’s disease and rheumatoid arthritis. BioDrugs 1998 Nov; 10: 397–422

    Article  PubMed  CAS  Google Scholar 

  9. Harriman G, Harper LK, Schaible TF. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF a treatment. Ann Rheum Dis 1999; 58 Suppl. 1: 161–4

    Article  Google Scholar 

  10. Dalesandro MR, Kinney CS, Frederick B, et al. Potential clinical relevance of the mechanism of inhibition of immune function by the mouse/human chimeric anti-TNF-α antibody, cA2 [abstract no. 1484]. Arthritis Rheum 1995 Sep; 38 Suppl.: S401

    Google Scholar 

  11. Maini RN, Taylor PC, Paleolog E, et al. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis 1999; 58 Suppl. 1: 156–60

    Article  Google Scholar 

  12. Feldmann M, Paleolog E, Taylor P, et al. The mechanism of action of anti-TNF-α therapy in rheumatoid arthritis [abstract no. SH 1.5]. Naunyn Schmiedebergs Arch Pharmacol 1998; 358(1) Suppl. 1:R197

    Google Scholar 

  13. Lorenz H-M, Antoni C, Valerius T, et al. In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis: short term cellular and molecular effects. J Immunol 1996 Feb 15; 156: 1646–53

    PubMed  CAS  Google Scholar 

  14. Paleolog EM, Hunt M, Elliot MJ, et al. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor a antibody in rheumatoid arthritis. Arthritis Rheum 1996 Jul; 39: 1082–91

    Article  PubMed  CAS  Google Scholar 

  15. Brennan FM, Browne KA, Green PA, et al. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy. Br J Rheumatol 1997 Jun; 36: 643–50

    Article  PubMed  CAS  Google Scholar 

  16. Perkins DJ, St Clair EW, Misukonis MA, et al. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor a monoclonal antibody (cA2). Arthritis Rheum 1998 Dec; 41: 2205–10

    Article  PubMed  CAS  Google Scholar 

  17. Taylor PC, Chapman P, Elliott MJ, et al. Reduced granulocyte traffic and chemotactic gradients in rheumatoid joints following treatment with anti-TNF-α monoclonal antibody [abstract no. 50]. Br J Rheumatol 1998; 37 Suppl. 1: 29

    Google Scholar 

  18. Tak PP, Taylor C, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor-α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996 Jul; 39: 1077–81

    Article  PubMed  CAS  Google Scholar 

  19. Tak PP, Taylor PC, Breedveld FC, et al. Infiltrate analysis of rheumatoid synovial tissue before and after anti-TNFA monoclonal antibody treatment [abstract no. 196]. Arthritis Rheum 1995 Sep; 38 Suppl.: S185

    Article  Google Scholar 

  20. Lorenz H-M, Hieronymus T, Grunke M, et al. In vivo blockade of TNF-α in patients with rheumatoid arthritis: indication for tachyphylaxis in long term ex vivo and in vitro effects after repeated infusion of chimeric monoclonal antibody cA2 [abstract no. P12]. Ann Rheum Dis 1998 Mar; 57: 190

    Google Scholar 

  21. Maurice MM, van der Graaff WL, Leow A, et al. Treatment of rheumatoid arthritis (R) with monoclonal anti-tumor necrosis factor a antibody (Anti-TNFα mAB) results in an accumulation of TH1 CD4+ T cells in the peripheral blood [abstract no. 798]. Arthritis Rheum 1998 Sep; 41 Suppl.: S165

    Google Scholar 

  22. Maini RN, Elliott MJ, Long-Fox A, et al. Clinical response of rheumatoid arthritis (RA) to anti-TNF-α monoclonal antibody (mab) is related to administered dose and persistence of circulating antibody [abstract no. 200]. Arthritis Rheum 1995 Sep; 38 Suppl.: S186

    Google Scholar 

  23. Paleolog E, Young S, McCloskey RV, et al. Angiogenesis as a therapeutic target in rheumatoid arthritis: serum vascular endothelial growth factor is decreased by anti-TNF-α therapy [abstract no. 147]. Clin Exp Rheumatol 1998 Mar–Apr; 16: 232

    Google Scholar 

  24. Hawkey CJ, Stack WA. Chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn’s disease [letter]. N Engl J Med 1998 Jan 29; 338: 333–4

    Article  PubMed  CAS  Google Scholar 

  25. Targan SR, Schaible TF. Chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn’s disease [reply letter]. N Engl J Med 1998 Jan 29; 338: 334

    Article  Google Scholar 

  26. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994 Oct 22; 344: 1105–10

    Article  PubMed  CAS  Google Scholar 

  27. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998 Sep; 41: 1552–63

    Article  PubMed  CAS  Google Scholar 

  28. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999 Dec 4; 354: 1932–9

    Article  PubMed  CAS  Google Scholar 

  29. Kavanaugh A, St Clair EW, McCune WJ, et al. Chimeric antitumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000; 27(4): 841–50

    PubMed  CAS  Google Scholar 

  30. Centocor Inc. Prescribing information for Remicade™ (infliximab) for IV injection. Malvern (PA), USA; Nov 1999

  31. Rezaian MM. Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? [letter]. Arthritis Rheum 1999 Aug; 42: 1779

    Article  PubMed  CAS  Google Scholar 

  32. Maini RN, Feldmann M, Schaible T, et al. Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? [reply letter]. Arthritis Rheum 1999 Aug; 42: 1779–80

    Article  Google Scholar 

  33. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum 1993 Dec; 36: 1681–90

    Article  PubMed  CAS  Google Scholar 

  34. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995 Jun; 38(6): 727–35

    Article  PubMed  CAS  Google Scholar 

  35. Paulus HE, Egger MJ, Ward JR, et al. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990 Apr; 33(4): 477–84

    Article  PubMed  CAS  Google Scholar 

  36. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor (X (cA2) in patients with rheumatoid arthritis. Lancet 1994 Oct 22; 344: 1125–7

    Article  PubMed  CAS  Google Scholar 

  37. Lipsky P, StClair W, Furst D, et al. 54-week clinical and radiographic results from the ATTRACT trial: a phase III study of infliximab (RemicadeRM) in patients with active RA despite methotrexate [abstract no. 1980]. Arthritis Rheum 1999 Sep; 42 Suppl.: S401

    Google Scholar 

  38. Antoni C, Maini R, Breedveld F, et al. Subgroup analyses show consistent clinical benefit in a 30-week double blind trial (ATTRACT) with an anti-TNF-α monoclonal antibody, infliximab, in rheumatoid arthritis patients on methotrexate [abstract no. 905]. Ann Rheum Dis 1999 Jun 6: 217

    Google Scholar 

  39. Centocor Inc. X-ray study suggests Remicade™ stops progression of rheumatoid arthritis [media release]; 15 Nov 1999 [3 pages]

  40. Hanauer SB. Safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999; 13 Suppl. 4: 16–22

    Article  PubMed  CAS  Google Scholar 

  41. Locksley RM, Wilson CB. Cell-mediated immunity and its role in host defense. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 4th ed. v. 1. New York: Churchill Livingstone, 1995: 102–48

    Google Scholar 

  42. Barland P, Lipstein E. Selection and use of laboratory tests in the rheumatic diseases. Am J Med 1996 Feb 26; 100 Suppl. 2A: 16S–23S

    Article  PubMed  CAS  Google Scholar 

  43. Hahn BH. Systemic lupus erythematosus. In: Wilson JD, Braunwald E, Isselbacher KJ, editors. Principles of internal medicine. 12th ed. v. 2. New York: McGraw-Hill, Inc., 1991: 1432–7

    Google Scholar 

  44. Charles PJ, Elliott MJ, Feldmann M, et al. Development of anti dsDNA antibodies in patients with rheumatoid arthritis treated with a chimeric monoclonal antibody to TNFalpha[abstract no. B114]. Rheumatol Eur 1995; 24 Suppl. 3: 108

    Google Scholar 

  45. Smolen JS, Steiner G, Breedveld FC, et al. Anti-TNFα therapy and drug induced lupus-like syndrome [abstract no. 906]. Ann Rheum Dis 1999 Jun 6; EULAR Suppl.: 217

  46. Pincus T, O’Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med 1999 Nov 16; 131: 768–74

    PubMed  CAS  Google Scholar 

  47. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously — predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986; 13: 841–5

    PubMed  CAS  Google Scholar 

  48. Huizinga TWJ, Breedveld FC. Cytokine-suppressive anti-inflammatory drugs: status of development in rheumatoid arthritis. Clin Immunother 1996 Nov; 6: 395–404

    Article  Google Scholar 

  49. Brooks PM. The Heberden oration 1997 treatment of rheumatoid arthritis: from symptomatic relief to potential cure. Br J Rheumatol 1998 Dec; 37: 1265–71

    Article  PubMed  CAS  Google Scholar 

  50. Markham A, Faulds D. Methotrexate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatoid arthritis and other immunoregulatory disorders. Clin Immunother 1994; 1(3): 217–44

    Article  Google Scholar 

  51. Furst DE. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. Br J Rheumatol 1997 Nov; 36: 1196–204

    Article  PubMed  CAS  Google Scholar 

  52. Furst DE, Keystone E, Maini RN, et al. Recapitulation of the round-table discussion — assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology 1999; 38 Suppl. 2: 50–3

    PubMed  Google Scholar 

  53. Fürst DE, Breedveld FC, Burmester GR, et al. Access to disease modifying treatments for rheumatoid arthritis patients. Ann Rheum Dis 1999; 58 Suppl. 1: 1129–30

    Article  Google Scholar 

  54. Immunex Corporation. EnbrelR: etanercept prescribing information. Seattle (WA); May 1999

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Harriet M. Lamb.

Additional information

Various sections of the manuscript reviewed by: F.C. Breedveld, Department of Rheumatology, University Hospital Leiden, Leiden, The Netherlands; D.E. Furst, Virginia Mason Research Center, University of Washington, Seattle, Washington, USA; J.R. Kalden, Department of Internal Medicine III, Institute for Clinical Immunology and Rheumatology, University of Erlangen-Nuremberg, Erlangen, Germany; A. Kavanaugh, Center for Innovative Therapy, University of California San Diego, Division of Rheumatology, Allergy and Immunology, La Jolla, California, USA; E.C. Keystone, Wellesley Hospital, Toronto, Ontario, Canada; J. Smolen, Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna, Austria.

Data Selection

Sources: Medical literature published in any language since 1980 on infliximab, identified using AdisBase (a proprietary database of Adis International, Auckland, New Zealand), Medline and EMBASE. Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search strategy: AdisBase search terms were ‘Infliximab’ or ‘Anti-human-TNF-alpha-monoclonal-antibody’ or ‘Anti-TNF-alpha-mab’ or ‘Anti-TNF-alpha-monoclonal-antibody-genzyme’ or Anti-TNF-monoclonal-antibody’ or ‘TA-650’ and ‘Rheumatoid-Arthritis’. Medline search terms were ‘Infliximab’ or ‘Anti-TNF-alpha-mab’ or ‘Anti-human-TNF-alpha-monoclonal-antibody’ or ‘Anti-TNF-monoclonal-antibody’ and ‘Rheumatoid-Arthritis’. EMBASE search terms were ‘Infliximab’ or ‘Anti-human-TNF-alpha-monoclonal-antibody’ or ‘Anti-TNF-alpha-mab’ or ‘Anti-TNF-monoclonal-antibody’ and ‘Rheumatoid-Arthritis’. Searches were last updated 1 June 2000.

Selection: Studies in patients with rheumatoid arthritis who received infliximab. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well-controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

Index terms: infliximab, rheumatoid arthritis, pharmacodynamics, pharmacokinetics, therapeutic use, adverse events.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markham, A., Lamb, H.M. Infliximab. Drugs 59, 1341–1359 (2000). https://doi.org/10.2165/00003495-200059060-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200059060-00010

Keywords

Navigation